| HOME >> BIOLOGY >> TECHNOLOGY |
As at December 31, 2007 the Company had 55,518,769 common shares, and 625,000 broker warrants were outstanding.
About GeneNews
--------------
GeneNews is focused on the application of functional genomics to enable early diagnosis and personalized therapeutic intervention based on disease-specific biomarkers. The Company has developed a novel approach, the Sentinel Principle(TM), to detect and stage virtually any disease or medical condition from a simple blood sample. GeneNews is currently applying the Sentinel Principle(TM) in major areas with unmet clinical needs such as cancer, arthritis, cardiovascular disease and neurological disorders. GeneNews' first product in development, ColonSentry(TM), is a convenient and patient-friendly blood-based test that can detect colon cancer. For more information on GeneNews, visit http://www.genenews.com.
This press release contains forward-looking statements, which reflect
the Company's current expectations regarding future events. The
forward-looking statements involve risks and uncertainties. Actual events
could differ materially from those projected herein. Investors should
consult the Company's ongoing quarterly filings and annual reports for
additional information on risks and uncertainties relating to these
forward-looking statements. The reader is cautioned not to rely on these
forward-looking statements. The Company disclaims any obligation to update
these forward-looking statements.
GeneNews Limited
CONSOLIDATED BALANCE SHEETS
(Expressed in Canadian dollars)
As at December 31
2007 2006
$ $
------------------------------------------------------------------
'/>"/>
| SOURCE GeneNews Limited Copyright©2008 PR Newswire. All rights reserved |